Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 20238366)

1.

Pegloticase for chronic gout.

Anderson A, Singh JA.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008335. doi: 10.1002/14651858.CD008335.pub2. Review.

PMID:
20238366
2.

[GOUT AND HYPERTENSION].

Belovol AN, Knyazkova II, Miroshnykova IA.

Lik Sprava. 2015 Jan-Mar;(1-2):32-8. Ukrainian.

PMID:
26118024
3.

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.

Zhang S, Zhang Y, Liu P, Zhang W, Ma JL, Wang J.

Clin Rheumatol. 2015 Jun 24. [Epub ahead of print]

PMID:
26099603
4.

Investigational drugs for hyperuricemia.

Shahid H, Singh JA.

Expert Opin Investig Drugs. 2015 Jun 14:1-18. [Epub ahead of print]

PMID:
26073200
5.

Gout: cartoonized and bagatellized and still left untreated. Time to change.

Jansen TL.

Clin Rheumatol. 2015 Jul;34(7):1317-9. doi: 10.1007/s10067-015-2986-y. Epub 2015 Jun 7. No abstract available.

PMID:
26050102
6.

Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.

Yu YK, Yu F, Ye C, Shen GF, Lei XM, Zhang ST, Hu SX.

Am J Ther. 2015 May 27. [Epub ahead of print]

PMID:
26035033
7.

Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC.

Rheumatol Int. 2015 May 20. [Epub ahead of print]

PMID:
25991397
8.

A Systematic Review of the Economic and Humanistic Burden of Gout.

Shields GE, Beard SM.

Pharmacoeconomics. 2015 May 13. [Epub ahead of print]

PMID:
25969152
9.

Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?

Peiteado D, Villalba A, Martín-Mola E, de Miguel E.

Clin Exp Rheumatol. 2015 May-Jun;33(3):385-90. Epub 2015 Apr 16.

PMID:
25898174
10.

Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.

Roughley MJ, Belcher J, Mallen CD, Roddy E.

Arthritis Res Ther. 2015 Apr 1;17(1):90. doi: 10.1186/s13075-015-0610-9.

11.

Pharmacogenetic considerations in the treatment of gout.

Roberts RL, Stamp LK.

Pharmacogenomics. 2015;16(6):619-29. doi: 10.2217/pgs.15.16. Epub 2015 Apr 16.

PMID:
25876828
12.

Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.

Bleyer AJ, Wright D, Alcorn H.

Clin Nephrol. 2015 May;83(5):286-92. doi: 10.5414/CN108481.

PMID:
25816806
13.

Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Hill EM, Sky K, Sit M, Collamer A, Higgs J.

J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.

PMID:
25807090
14.

Study for Updated Gout Classification Criteria (SUGAR): identification of features to classify gout.

Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher HR, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire C, Cavagna L, Lin C, Chou YY, Tausche AK, Vargas-Santos AB, Janssen M, Chen JH, Slot O, Cimmino MA, Uhlig T, Neogi T.

Arthritis Care Res (Hoboken). 2015 Mar 16. doi: 10.1002/acr.22585. [Epub ahead of print]

PMID:
25777045
15.

Seasonality of gout in Korea: a multicenter study.

Choi HJ, Lee CH, Lee JH, Yoon BY, Kim HA, Suh CH, Choi ST, Song JS, Joo H, Choi SJ, Lee JS, Shin K, Jun JB, Baek HJ.

J Korean Med Sci. 2015 Mar;30(3):240-4. doi: 10.3346/jkms.2015.30.3.240. Epub 2015 Feb 16.

16.

Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.

Frampton JE.

Drugs. 2015 Mar;75(4):427-38. doi: 10.1007/s40265-015-0360-7.

PMID:
25724536
17.

Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.

Yamamoto T, Hidaka Y, Inaba M, Ishimura E, Ooyama H, Kakuta H, Moriwaki Y, Higami K, Ohtawara A, Hosoya T, Nishikawa H, Taniguchi A, Ueda T, Yamauchi T, Fujimori S, Mineo I, Yamanaka H.

Mod Rheumatol. 2015 Mar 12:1-5. [Epub ahead of print]

PMID:
25671406
18.

Interleukin-1 as a therapeutic target in gout.

Dumusc A, So A.

Curr Opin Rheumatol. 2015 Mar;27(2):156-63. doi: 10.1097/BOR.0000000000000143.

PMID:
25633244
19.

Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.

Richette P, Frazier A, Bardin T.

Curr Opin Rheumatol. 2015 Mar;27(2):170-4. doi: 10.1097/BOR.0000000000000149.

PMID:
25594854
20.

Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.

An G, Liu W, Duan WR, Nothaft W, Awni W, Dutta S.

AAPS J. 2015 Mar;17(2):416-26. doi: 10.1208/s12248-014-9709-1. Epub 2015 Jan 8. Erratum in: AAPS J. 2015 Mar;17(2):481-92.

PMID:
25567367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk